Is Ki-67 Really Useful as a Predictor for Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer?

被引:0
|
作者
Dave, Sukruti [1 ]
Choudhury, Arpan [2 ]
Alurkar, Shirish S. [1 ]
Shah, Akash M. [1 ]
机构
[1] Apollo Hosp Int Ltd Apollo Hosp Ahmedabad, Dept Med Oncol, Ahmadabad, Gujarat, India
[2] Apollo Hosp Int Ltd Apollo Hosp Ahmedabad, Dept Surg Oncol, Ahmadabad, Gujarat, India
关键词
Oncology; Breast cancer; ki67; Neoadjuvant chemotherapy; Response evaluation; PATHOLOGICAL COMPLETE RESPONSE; SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; CLINICAL-SIGNIFICANCE; RANDOMIZED-TRIAL; KI67; TRASTUZUMAB; TUMOR; THERAPY; MARKERS;
D O I
10.1007/s13193-023-01822-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neoadjuvant chemotherapy (NACT) is routinely offered to operable locally advanced breast cancer (LABC) patients desirous of breast conservation surgery and inoperable LABC patients. Pathological complete response (pCR) following chemotherapy is recognized as a surrogate for survival outcomes in high grade tumour subtypes. Many biological and tumor characters have been shown to predict pCR. The current study was performed with the aim of investigating the ability of Ki-67 in predicting pCR with NACT in breast cancer patients. A total of 105 patients with locally advanced breast cancer who completed NACT followed by surgery were included in this study from January 2020 till December 2022. Patients with advanced metastatic breast carcinoma, who did not give consent for NACT, who did not complete NACT and who did not undergo surgery were excluded. All patients were assessed for Ki-67 score on core-needle biopsy samples and response rate was assessed clinically and by histopathological examination of resected specimen. Quantitative variables were compared using unpaired t-test or Mann-Whitney 'U' test and for categorical variables Chi-square or Fisher's exact test were used. Receiver operating char-acteristic (ROC) curve analysis was performed to assess the predictive potential of Ki-67 expression levels in predicting pCR. To identify the predictive factors associated with pCR, univariate analysis was performed. The P value < 0.05 was considered as statistically significant. Mean age was 51.57 +/- 10.8 years. 51 patients achieved clinical complete response (cCR) and 33 achieved pCR after NACT. Mean Ki-67 index in overall study population, in pCR group and no pCR group was 46.44 +/- 22.92%, 51.60 +/- 22.3% and 44.06 +/- 22.7%, respectively. On univariate analysis, ER negativity, PR negativity and Her 2neu positivity were found predictive of pCR. On subgroup analysis, TNBC and Her 2neu positive sub groups were associated with higher cCR and pCR rate. We found no significant association between Ki-67 and pCR. This result may be confounded by the fact that a significant duration of the study was in the COVID-19 pandemic. Validation of this data is required in a large prospective study.
引用
收藏
页码:44 / 52
页数:9
相关论文
共 50 条
  • [31] Ki67 expressions after neoadjuvant chemotherapy in women with locally advanced breast cancer in north western Algeria
    Benchiha, N. N.
    Klouche, L.
    Houti, L.
    [J]. HISTOPATHOLOGY, 2022, 81 : 32 - 33
  • [32] Ki-67 CAN BE USED AS A PREDICTIVE FACTOR FOR THE EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
    Kozar, N.
    Sikosek, N. Cas
    Arko, D.
    Ravnik, M.
    Takac, I.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 115 - 115
  • [33] Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
    Acs, Balazs
    Zambo, Veronika
    Vizkeleti, Laura
    Szazs, A. Marcell
    Madaras, Lilla
    Szentmartoni, Gyongyver
    Tokes, Timea
    Molnar, Bela A.
    Molnar, Istvan Artur
    Vari-Kakas, Stefan
    Kulka, Janina
    Tokes, Anna-Maria
    [J]. DIAGNOSTIC PATHOLOGY, 2017, 12 : 1 - 12
  • [34] Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
    Balázs Ács
    Veronika Zámbó
    Laura Vízkeleti
    A. Marcell Szász
    Lilla Madaras
    Gyöngyvér Szentmártoni
    Tímea Tőkés
    Béla Á. Molnár
    István Artúr Molnár
    Stefan Vári-Kakas
    Janina Kulka
    Anna-Mária Tőkés
    [J]. Diagnostic Pathology, 12
  • [35] KI-67 CAN BE USED AS A PREDICTIVE FACTOR FOR THE EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
    Kozar, N.
    Sikosek, N. Cas
    Arko, D.
    Ravnik, M.
    Takac, I.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 635 - 635
  • [36] Biomarker panel (TheraPrint) analyzed as a predictor of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
    Beitsch, Peter D.
    Stork, Lisette
    De Snoo, Femke
    Peeters, Justine
    Whitworth, Pat W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: Focus on Ki-67 and molecular subtypes
    Rapoport, B. L.
    Barnard-Tidy, J.
    Van Eeden, R. I.
    Smit, T.
    Nayler, S.
    Benn, C.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 37 - 37
  • [38] Neoadjuvant chemotherapy in locally advanced breast cancer
    Singh, G
    Singh, DP
    Gupta, D
    Muralikrishna, BV
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 1996, 61 (01) : 38 - 41
  • [39] Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
    Specht, Jennifer
    Gralow, Julie R.
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2009, 19 (04) : 222 - 228
  • [40] Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
    Iqbal, Javeria
    Shafi, Alam Ara
    Alharthi, Bandar N.
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2014, 24 (11): : 845 - 848